Treatment of neoplastic disease with oral interferon

dc.creator	Cummins, Joseph M.
dc.date.accessioned	2019-06-17T16:55:08Z
dc.date.available	2019-06-17T16:55:08Z
dc.date.issued	1998-10-20
dc.identifier.uri	https://hdl.handle.net/1969.1/176595
dc.description.abstract	Neoplastic diseases are treated by the administration of human interferon, particularly IFN-α, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. The interferon is administered in a solid dosage from, e.g., a saliva-dissolvable lozenge.	en
dc.language	eng
dc.publisher	United States. Patent and Trademark Office
dc.rights	Public Domain (No copyright - United States)	en
dc.rights.uri	http://rightsstatements.org/vocab/NoC-US/1.0/
dc.title	Treatment of neoplastic disease with oral interferon	en
dc.type	Utility patent	en
dc.format.digitalOrigin	reformatted digital	en
dc.description.country	US
dc.contributor.assignee	The Texas A&M University System
dc.identifier.patentapplicationnumber	08/479958
dc.subject.uspcprimary	424/85.7
dc.subject.uspcother	424/85.4
dc.subject.uspcother	424/85.6
dc.subject.uspcother	424/464
dc.date.filed	1995-06-07
dc.publisher.digital	Texas A&M University. Libraries
dc.subject.cpcprimary	A61K 38/21
dc.subject.cpcprimary	A61K 38/212
dc.subject.cpcprimary	Y10S 435/811